Ann: Quarterly Activity Report and Appendix 4C, page-11

Looking over the invest preso it would seem that we are progressing in China with the approvals. Also the test kits etc in Colombia seems to be very interesting and on approval would allow us to sell our products in four different countries. That sounds BIG.

Also the UK market looking interesting

We may see some further updates based on the below in the coming weeks.

IMO we still have a VERY LOW market cap for what we currently have



Meanwhile, the Company’s Ovine Collagen division reported an 18.8% pcp increase
in revenue to just over $0.1 million due to orders from a major cosmetics
manufacturer in Thailand. In China, Holista secured the approval for its Material
Safety Data Sheet (MSDS) for bulk ovine collagen from Chinese Customs. This will
allow the shipping of bulk raw collagen for the final testing that is required to secure
the necessary approvals in China.

The registration of the previously announced SARS-CoV-2 rapid test kit branded as
Gene Sign is pending final approval in Colombia and will have corresponding
approvals in Brazil, Argentina and Mexico in a unique four-country arrangement. In
North America, Gene Sign is undergoing approval under the Medical Device Single
Audit Program (MDSAP) with the United States Food and Drug Administration
(FDA).
Gene Sign’s Reverse-Transcription Loop-mediated isothermal amplification (RTLAMP) technology is undergoing final evaluation in the United Kingdom by the
COVID Testing Devices Authorisation (CTDA). RT-LAMP technology is accepted by
the US FDA as an alternative to Reverse Transcription Polymerase Chain Reaction
(RT-PCR) as it is cheaper and more efficient (Note 3).